family with sequence similarity 107 member BGenealiases: C10orf45 · HITS
Q-omics provides the consensus-scored FAM107B profile across patient tissues and cancer cell-line models. FAM107B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, FAM107B is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, FAM107B protein abundance shows 27,241 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, COAD, and LSCC as cancer lineages where FAM107B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM107B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM107B survival associations across molecular data types. FAM107B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM107B RNA expression–survival associations across cancer types. High FAM107B expression shows unfavorable associations in UVM and LUAD, but favorable associations in SKCM, HNSC, KIRC and KICH. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for FAM107B RNA expression.
This table summarizes FAM107B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM107B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM107B shows lower tumor expression in COAD, KICH, KIRP, KIRC, LUSC and THCA. The COAD box plot shows higher FAM107B RNA expression in normal versus tumor tissue (log2 FC = −1.611, t-test p < 0.001).
This table shows molecular features associated with FAM107B in patient tissues and cancer cell lines. In patient samples, FAM107B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM107B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
